MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.73
-0.82
-6.05%
Opening 10:19 04/23 EDT
OPEN
12.56
PREV CLOSE
13.55
HIGH
12.76
LOW
12.56
VOLUME
4.34K
TURNOVER
--
52 WEEK HIGH
21.99
52 WEEK LOW
12.24
MARKET CAP
812.24M
P/E (TTM)
217.98
1D
5D
1M
3M
1Y
5Y
Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C...
PR Newswire · 1d ago
Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
PR Newswire · 04/07 21:00
Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the publication of its Annual Report for the year ended 31 December 2020, which is available on the Company's website www.pharming.com under Investors/Fina...
PR Newswire · 04/06 22:30
The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 25)
Benzinga · 03/26 11:28
Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Their official appointments will b...
PR Newswire · 03/23 07:00
Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference
PR Newswire · 03/16 13:10
Pharming Group to Present at BioCapital Europe 2021
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021. BioCapital Europe, organized...
PR Newswire · 03/11 06:00
Pharming Group reports financial results for full year 2020
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the full year ended 31 December 2020.
PR Newswire · 03/04 06:00
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHAR. Analyze the recent business situations of Pharming Group N.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers kinds of Pharming Group N.V. stock information, including NASDAQ:PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.